Myriad Genetics (MYGN)
(Delayed Data from NSDQ)
$28.02 USD
+0.01 (0.04%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $28.03 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MYGN 28.02 +0.01(0.04%)
Will MYGN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MYGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MYGN
INCY or MYGN: Which Is the Better Value Stock Right Now?
Myriad Genetics (MYGN) Expands in MRD Testing With New Collab
MYGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Myriad Genetics (MYGN) Advances in MRD Space With New Patent
Myriad Genetics (MYGN) and GSK Unite to Boost HRD Testing
Myriad Genetics (MYGN) Banks on Innovation Amid Macro Woes
Other News for MYGN
What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
Myriad Genetics announces results from nationwide Cancer Risk Survey
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
Myriad Genetics Earns 2024 Great Place To Work® Certification™